InsidersTradesSigma
Total declarations
Companies
▲ Purchases (5 ops.)
▼ Sales (0 ops.)
Insider track record
ExecutiveDisclosed buys
5
Disclosed sells
0
T+90 hit rate
75%
T+90 mean return
+3.7%
Across 4 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Explore the detailed record of transactions filed by HSIAO JANE PH D, Chief Technology Officer. Officer active across 2 companies, notably Asensus Surgical, INC.. Cumulatively, 8 filings have been published. Breakdown: 5 buys · 0 sell. Total volume traded: €291k. Activity tracked since 1 July 2021. The latest transaction was disclosed on 24 July 2024 (Attribution). Regulator: SEC (Form 4). All data is free.
Declarations8 total
500,000 shares0Common StockSEC:0000950170-24-087039:0
150,000 shares@ US$0.9545.0% of flowCommon StockSEC:0000950170-24-005070:0
Ideal exit: 13 Oct 2024 (T+270)
150,010 shares@ US$0.872641.1% of flowCommon StockSEC:0000950170-24-002743:0
Ideal exit: 1 Oct 2024 (T+270)
34,058 shares@ US$1.2613.8% of flowCommon StockSEC:0001209191-23-054918:0
Ideal exit: 6 Aug 2024 (T+270)
10 shares@ US$3.730.0000% mcap50.0% of flowCommon StockSEC:0001209191-21-050591:0
Ideal exit: 6 May 2022 (T+270)
10 shares@ US$3.730.0% of flowCommon StockSEC:0001209191-21-050591
Ideal exit: 6 May 2022 (T+270)
29,231 shares0Common StockSEC:0001209191-21-045178:0
29,231 shares0Common StockSEC:0001209191-21-045178
8 of 8 declarations
About HSIAO JANE PH D
Jane Hsiao, Ph.D. is the Vice Chairman & CTO at ASENSUS SURGICAL, INC. and OPKO HEALTH, INC. In these roles, she is responsible for the technical direction and innovation of the companies. Hsiao brings valuable expertise in research and development, contributing to advancements in medical technologies. Her commitment to innovation and improving patient care is essential in guiding ASENSUS and OPKO's projects. She collaborates with research teams to ensure the success of technological initiatives.
